Health Care & Life Sciences » Pharmaceuticals | Karessa Pharma Holding AB

Karessa Pharma Holding AB | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2014
2015
2016
2017
Cost of Goods Sold (COGS) incl. D&A
-
-
-
636.00
Gross Income
-
-
-
636.00
SG&A Expense
3,266.00
13,072.00
10,855.00
14,262.00
EBIT
3,266.00
13,072.00
10,866.00
14,898.00
Unusual Expense
-
-
-
33,500.00
Non Operating Income/Expense
-
259.00
342.00
643.00
Pretax Income
2,933.00
12,590.00
10,466.00
47,626.00
Consolidated Net Income
2,933.00
12,590.00
10,466.00
47,626.00
Net Income
2,933.00
12,590.00
10,466.00
47,626.00
Net Income After Extraordinaries
2,933.00
12,590.00
10,466.00
47,626.00
Net Income Available to Common
2,933.00
12,590.00
10,466.00
47,626.00
EPS (Basic)
0.56
1.14
0.95
4.33
Basic Shares Outstanding
5,200.50
11,000.00
11,000.00
11,000.00
EPS (Diluted)
0.56
1.10
0.95
4.33
Diluted Shares Outstanding
5,200.50
11,450.00
11,000.00
11,000.00
EBITDA
3,266.00
13,072.00
10,855.00
14,262.00
Non-Operating Interest Income
333.00
223.00
58.00
129.00

About Karessa Pharma Holding AB

View Profile
Address
Lahällsvägen 48
Täby AB 183 30
Sweden
Employees -
Website http://www.karessa.se
Updated 09/14/2018
Karessa Pharma Holding AB engages in the development and commercialization of products in the therapeutic area of erectile dysfunction. Its projects include K-01, K-02, and K-03. The company was founded by Fredrik Hubinette on September 11, 2013 and is headquartered in Täby, Sweden.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.